Trial Profile
A retrospective, observational, single center study of cobimetinib in combination with vemurafenib in patients with BRAF V600-mutated metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2017
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jul 2017 New trial record